Abstract
COVID-19 vaccination is being conducted in over 190 countries/regions to control SARS-CoV-2 transmission and return to a pre-pandemic lifestyle. However, understanding when non-pharmaceutical interventions (NPIs) can be lifted as immunity builds up remain a key question for policy makers. To address it, we built a data-driven model of SARS-CoV-2 transmission for China. We estimated that to prevent the escalation of local outbreaks to widespread epidemics, stringent NPIs need to remain in place at least one year after the start of vaccination. Should NPIs alone be capable to keep the reproduction number (Rt) around 1.3, the synergetic effect of NPIs and vaccination could reduce up to 99% of COVID-19 burden and bring Rt below the epidemic threshold in about 9 months. Maintaining strict NPIs throughout 2021 is of paramount importance to reduce COVID-19 burden while vaccines are distributed to the population, especially in large populations with little natural immunity.
Competing Interest Statement
H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. M.A. has received research funding from Seqirus. None of those research funding is related to COVID-19. All other authors report no competing interests.
Clinical Trial
No trial ID cause this is a modelling study
Funding Statement
The study was supported by grants from the National Science Fund for Distinguished Young Scholars (No. 81525023), Key Emergency Project of Shanghai Science and Technology Committee (No 20411950100), National Science Fund for Distinguished Young Scholars (No. 81903373), European Union Grant 874850 MOOD (MOOD 000).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All these data were in the public domain. Ethical review for the re-use of these secondary data is not required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* These authors contributed equally to this work.
↵† These authors are joint senior authors contributed equally to this work.
We have emphasized the main message of our analysis, which is showing to what extent we need to rely on NPIs while vaccines roll out. Accordingly, we have changed the title of the manuscript that now reads "To what extent do we need to rely on non-pharmaceutical interventions while COVID-19 vaccines roll out in 2021?". We have rewritten most of the Introduction to better clarified the aim of this study and its merit in supporting the response in China (home of about 18% of the world population). We have added a scenario analysis to project impact of vaccination should a new COVID-19 wave start when a different fraction of the population has already been vaccinated. We have added a set of sensitivity analyses to consider the potential impact of new variants with increased transmissibility and higher mortality rates, different vaccine efficacies and vaccine coverage.
Data Availability
Should the manuscript be accepted, all data and codes will be provided on GitHub.
